Menu Search
Equities

Stenocare A/S

  • Add to watchlist
  • Add to portfolio
  • Add an alert
S7C:FRA

Stenocare A/S

Actions
  • Price (EUR)0.183
  • Today's Change-0.005 / -2.40%
  • Shares traded1.42k
  • 1 Year change+231.52%
  • Beta0.6222
Data delayed at least 15 minutes, as of Feb 16 2026 08:55 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

STENOCARE A/S is a Denmark-based company, which is engaged in the production of medical cannabis products to patients. The Company’s business model has two divisions: Import and wholesale of finished medical cannabis products for Danish patients, as well as Operate own cultivation- and production facility in Denmark to produce finished cannabis products for Danish and European patients. The Company distributes its products through pharmacies and hospitals. Stenocare's head office is located in Randers, Denmark.

  • Revenue in DKK (TTM)5.67m
  • Net income in DKK-24.58m
  • Incorporated2017
  • Employees8.00
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		STENO:CPH since
announced		Transaction
value
Canngros ApSAnnounced17 Nov 202517 Nov 2025Announced-36.56%1.77m
Data delayed at least 15 minutes, as of Feb 16 2026 11:06 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.